Lou Gehrig’s disease

Patients with insurance coverage say the cost set by drugmaker Amylyx Pharmaceutical is fueling insurance delays or denials, and sometimes exorbitant out-of-pocket expenses.

The ruling is a remarkable turnaround for the much-debated medication that was previously rejected by the same group this year.

The vote by the agency's health advisers is a potential setback for patient groups who have lobbied for the medication’s approval for more than a year.

On Wednesday, a panel of FDA advisers is scheduled to take a nonbinding vote on whether the drug from Amylyx Pharmaceuticals should be approved.

The agency may soon approve another drug for a deadly neurodegenerative disease based on partial data that’s being debated by experts.

Scientists who conducted the study say they couldn't determine exactly why the rate was higher but suggested that repetitive head impacts and traumatic brain injuries may play a role.

Scientists say new drugs are on the way for patients with ALS. The latest is a two-drug combo that appears to slow the progression of the fatal nerve disease with a modest but meaningful benefit.

Structures inside healthy brain cells nimbly move from one state to the next to perform different functions. But in certain degenerative brain diseases, scientists now think, that process gets stuck.

Gov. Rick Scott signed several drug bills into law on Monday and said he will do the same for a measure that fights human trafficking.One of the drug…

Researchers with the Mayo Clinic in Jacksonville have found an abnormal protein that collects in the brains of patients who have Lou Gehrig’s disease or…